| 000 | 01863 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517150718.0 | ||
| 264 | 0 | _c20170424 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1524-4733 | ||
| 024 | 7 |
_a10.1016/j.jval.2016.04.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOthus, Megan | |
| 245 | 0 | 0 |
_aAccounting for Cured Patients in Cost-Effectiveness Analysis. _h[electronic resource] |
| 260 |
_bValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _c04 2017 |
||
| 300 |
_a705-709 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aBias |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycoproteins _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIpilimumab |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvivors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBansal, Aasthaa | |
| 700 | 1 | _aKoepl, Lisel | |
| 700 | 1 | _aWagner, Samuel | |
| 700 | 1 | _aRamsey, Scott | |
| 773 | 0 |
_tValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _gvol. 20 _gno. 4 _gp. 705-709 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jval.2016.04.011 _zAvailable from publisher's website |
| 999 |
_c27079548 _d27079548 |
||